Astellas Gets U.S. Clearance For Antibiotic After Some FDA Troubles
This article was originally published in PharmAsia News
Executive SummaryAstellas Pharma says it has received clearance from the U.S. FDA for its Vibativ (televancin) antibiotic. Atellas plans to launch the drug, which it developed jointly with U.S.-based Theravance, by the end of the year. Atellas considers the drug a key one for its portfolio, particularly at a time when it has experienced problems getting some of its drugs approved by the U.S. agency. Vibativ is a once-daily injectable antibiotic for treating complicated skin infections. (Click here for more
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.